Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AstraZeneca's Tozorakimab?
Tozorakimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Tozorakimab by AstraZeneca for Chronic Bronchitis: Likelihood of Approval
Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Chronic Bronchitis. According to GlobalData, Phase II...
Tozorakimab by AstraZeneca for Asthma: Likelihood of Approval
Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...